Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg)

This 12mg blend combines Fragment 176-191 6mg, Mod GRF (1-29) 3mg, and Ipamorelin 3mg in a single vial, synthesized and lyophilized in the USA.

Each vial of Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg) contains a pre-weighed ratio of Fragment 176-191 6mg, Mod GRF (1-29) 3mg, Ipamorelin 3mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Studies evaluating Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg) typically focus on receptor activation profiles and downstream metabolic signaling under controlled in-vitro conditions.

Researchers using Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Interest in Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg) has grown alongside comparative work on incretin-related pathways and substrate utilization in cultured systems.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Fragment 176-191 & Mod GRF (1-29) & Ipamorelin Blend (12mg). Summaries are provided for orientation only and reflect the cited sources.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice^[1] — This study examined the effects of human growth hormone and its lipolytic fragment AOD9604 on lipid metabolism after chronic treatment in obese mice and in beta-3 adrenergic receptor knockout mice. The authors investigated the fragment's capacity to promote fat loss in these models. The findings indicated that the hGH-derived fragment exerts lipid-mobilizing activity, providing a basis for the research use of Fragment 176-191. (Endocrinology 2001)

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone^[2] — This study characterized the metabolic and lipolytic activity of AOD9604, a synthetic lipolytic domain of human growth hormone. The authors evaluated the peptide's effects on lipid metabolism in animal models. The results suggested that AOD9604 retains fat-mobilizing actions related to the larger hGH molecule, supporting its study as a lipolytic agent. (Hormone Research 2000)

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults^[3] — This study assessed the growth hormone and IGF-I responses to a single injection of the long-acting GHRH analog CJC-1295 in healthy adults. The authors examined the duration and magnitude of hormonal elevation following administration. The findings indicated that CJC-1295 produces prolonged stimulation of the GH-IGF-I axis, providing reference for the GHRH analog family to which Mod GRF 1-29 belongs. (The Journal of Clinical Endocrinology & Metabolism 2006)

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog^[4] — This study examined whether continuous stimulation by the long-acting GHRH analog CJC-1295 alters the pulsatile pattern of growth hormone secretion. The authors reported that GH pulsatility was preserved while trough GH and IGF-I levels were raised. The findings suggested that GHRH-class peptides amplify GH output without disrupting its physiological pulsatile rhythm. (The Journal of Clinical Endocrinology & Metabolism 2006)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[5] — This study tested whether the growth-hormone-releasing peptide ipamorelin could stimulate longitudinal bone growth in rats. The authors examined the effects of ipamorelin administration on bone growth and related IGF-1 responses. The results suggested that ipamorelin promotes skeletal growth through stimulation of the GH-IGF-1 axis, supporting its role in this blend. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[6] — This study evaluated the pharmacokinetics of ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to nasal absorption. The authors compared systemic exposure after different routes of administration. The findings indicated that ipamorelin has favorable absorption characteristics among the GHRP-class peptides. (Xenobiotica 1999)

References

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001. pubmed.ncbi.nlm.nih.gov/11713213/
2. Ng FM, et al.. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research. 2000. pubmed.ncbi.nlm.nih.gov/11146367/
3. Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
4. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
5. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
6. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.